Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 192

The DOI matches its Crossref record.

Rituximab in the treatment of polyneuropathy associated with anti‐MAG antibodies

Open access
Renaud, Susanne, Gregor, Michael, Fuhr, Peter, Lorenz, Delia, Deuschl, Günther, Gratwohl, Alois, Steck, Andreas J. · 2003 · Muscle & Nerve

Abstract

No causative or curative therapy exists for the polyneuropathy associated with antibodies to myelin‐associated glycoprotein (anti‐MAG). Rituximab is a mouse‐human chimeric antibody that specifically eliminates B‐cells and B‐cell precursors. Preliminary results suggest a beneficial effect on antibody‐dependent autoimmune diseases. Nine patients with an anti‐MAG–associated IgM polyneuropathy received rituximab once weekly for 4 weeks. In all patients, the number of B‐cells in the peripheral blood declined below levels of detection, and the IgM levels decreased between 35% and 82% (median, 58%). In eight patients, lowering of the anti‐MAG antibody titers of more than 52% was observed. Clinical status improved in six patients, remained stable in two, and worsened in one. The motor nerve conduction velocity improved by at least 10% in one ulnar nerve in seven patients and worsened in two. Rituximab was well tolerated and is a promising new drug in the treatment of patients with anti‐MAG–associated polyneuropathy. Muscle Nerve 27:611–615, 2003

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/mus.10359

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 192

Metadata

Authors
Renaud, S., Gregor, M., Fuhr, P., Lorenz, D., Deuschl, G., Gratwohl, A., & Steck, A. J.
Venue
Muscle & Nerve
Publisher
Wiley
Published
2003-03-04
Volume
27
Issue
5
Pages
611-615
ISSN
  • 0148-639X (ISSN-L)
  • 1097-4598
OpenAlex
W1971533561
Cited by
192
References
0
FWCI
12.43
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Rituximab in the treatment of polyneuropathy associated with anti‐MAG antibodies. https://app.cochat.ai/papers/10.1002/mus.10359
The paper
Renaud, S., Gregor, M., Fuhr, P., Lorenz, D., Deuschl, G., Gratwohl, A., & Steck, A. J. (2003). Rituximab in the treatment of polyneuropathy associated with anti‐MAG antibodies. Muscle & Nerve. https://doi.org/10.1002/mus.10359

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.